

Certificate of Analysis

Live Cell count	2 million per vial
Viability	89%
CD8+	99.9%
CD8+MART-1Tetramer+	0.2%
CD8+WT-1Tetramer+	98.3%
Sterility	Negative for Bacteria, Yeast and Fungi
Mycoplasma	Negative

Donor Information


Donor ID	398
Age	41
Gender	Female
Race	Caucasian
Height	5'6"
Weight	142
ABO Type	A positive

HLA typing

	Allele 1	Allele 2
HLA-A	*02	*03
HLA-B	*07	*39
HLA-C	*07	*07
HLA-DRB1	*08	*15


Donors are tested for the blood borne pathogens HIV-1 and 2, Hepatitis B, Hepatitis C and HTLV-1 and are negative. Cells should still be handled as if potentially infectious following biosafety level 2 procedures

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE



MART-1 tetramer = MART-1_{26-35 A27L} peptide (ELAGIGILTV) HLA-A*0201-PE iTag MHC Tetramer (MBL International, Woburn, MA); WT-1 tetramer = WT-1 peptide (RMFPNAPYL)/HLA-A*0201-PE iTag MHC Tetramer (MBL International, Woburn, MA)

IFN-gamma Secretion



20,000 T cells were plated in a 96-well round-bottom plate alone or in the presence of 20,000 T2 cells, a B-LCL expressing HLA-A*0201) alone or in the presence of increasing concentrations of HLA-A*0201 restricted MART-1_{26-35 A27L} peptide (ELAGIGILTV) or HLA-A*0201 restricted WT-1 peptide (RMFPNAPYL). Culture media used is RPMI 1640 and 10% FBS. After an overnight (18-24h) incubation period, supernatant was collected from each well. IFN-γ concentration was analyzed using the Meso Scale Discovery IFN-γ assay.

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE